The results of the present study indicated significant differences between the MPH and experimental groups in terms of hormonal, spermographic, and histopathologic characteristics, as well as weight. In this regard, no significant difference was observed between experimental groups regarding LH and testosterone levels, sperm count and motility, Leydig cell hyperplasia, spermatogenesis, congestion and necrosis levels, total body weight, and testis weight. However, there was no significant difference between the control and the experimental groups considering FSH, maturation arrest, and edema levels. The HD and control groups were significantly different in terms of LH levels, body weight, and testis weight (
Figures 3 and
4). However, no such difference was observed between the LD and control groups. In addition, there was no significant difference between the two experimental groups in terms of any of the evaluated variables.
The current study revealed a lower body weight in the high-dose MPH group, which is in line with the findings of several studies (
7,
14). In this regard, Carias et al. reported a decrease in food intake and body weight in rats treated with high-dose MPH. They also observed a decrease in water intake in both high- and low-dose groups. In the mentioned study, 8 and 30 ng/ml levels were considered as the peak serum concentrations in the low- and high-dose groups, respectively (
15). Furthermore, Robison et al. observed that high-dose MPH decreased total weight in male and female rats while this treatment increased food intake only in females. A possible explanation for this result is that the compensation of energy loss resulted from MPH-induced hyperactivity (
16). Other trials that treated rats with low doses of MPH reported insignificant weight alterations (
9,
17). Similarly, our results indicated a significant difference only in the high-dose group. Based on our findings and those of the previous studies, it seems that there are some dose-dependent relationships between treatment and weight loss (
17-
19). Similar results have been reported in human studies. Weight reduction is the most common adverse effect of MPH in adults (
20,
21). These findings may explain the relationship between obesity and ADHD (
22), the role of MPH in the treatment of ADHD-related obesity (
23), and the possible mechanism of decreased appetite due to the drug (
24). Several pieces of evidence have shown a transient decrease following MPH administration in both humans (
19,
25-
30) and animals (
17,
18,
31), which makes a rebound after treatment cessation (
11). In line with the present results, previous studies have demonstrated a decrease in the testis weight, in addition to the prostate and seminal vesicles weight following MPH treatment in rats (
11,
32). Teo et al. reported a rebound weight gain in the prostate 30 days after the last MPH administration (
18). Montagnini et al. observed no significant alteration 40 days after the experiment (
9). According to the blocking effect of MPH on Noradrenaline (NA) and Dopamine (DA) transporters, the presence of DA and NA receptors in testicular tissue may directly affect MPH on the testis (
33,
34). Furthermore, germ cell depletion has been mentioned as the possible role player in the literature (
35). The results obtained by Fazelipour et al., investigating hormonal changes, namely elevated LH, decreased testosterone, and insignificant changes of FSH, are relatively in line with our findings. They believe that despite the role of reduced testosterone secretion by Leydig cells and the subsequent rise in LH in these changes, the increased liver metabolism of the testosterone-producing enzyme could be the point and the insignificant elevation in FSH reinforces this hypothesis (
6,
7,
36). The literature is indicative of the effect of MPH on pulsatile gonadotropin-releasing hormone (GnRH) release (
36) and direct impairment of Leydig cells (
6). However, there are also reports on the transient negative effect of MPH on testosterone, as well as body and testis weight (
6,
37). There are multiple studies indicating spermatogenesis and spermiogenesis impairments, including decreased sperm count and altered morphology (
7,
9,
11,
38). In an investigation carried out by Cansu et al. (
11), more negative effects were observed in the high-dose group, which is in line with the dose-dependency of some MPH adverse effects. They ascribed this alteration to the increased p53 immunoreactive cell number in the high-dose group, higher testis apoptotic cell count, and lower Transforming Growth Factor (TGF)-β1 activity in high- and low-dose groups. TGF-β1 has both stimulatory and inhibitory effects on cell proliferation and spermatogenesis in rats (
39-
45). Nonetheless, it is not present in human seminiferous ducts (
46). MPH affects dopamine transport, D2 receptors, serotonin, and noradrenaline (
31,
35,
47), and D2 and α- and β-adrenergic receptors are expressed in the testis and spermatozoa of rat (
33,
34). The toxicity caused during spermatogenesis could lead to apoptosis (
48,
49). The increased apoptosis and p53 expression are discussed as the causes of sperm count decrease in some other studies (
7,
11,
38). Due to the effect of the GnRH level on FSH (
50) and the function of FSH in the primary stages of spermatogenesis (
51-
53), FSH changes could disrupt the spermatogenesis process. However, no significant difference was observed in the FSH levels in the current study and the one performed by Fazelipour et al. (
7). In the present study, Leydig cell hyperplasia was observed in the HD group, which is contrary to the previous findings indicating the decreased Leydig cell count (
8) or the absence of significant changes (
9). Accordingly, further studies are needed to explain the exact effect of MPH on Leydig cells. Necrosis was another significantly increased parameter in the MPH groups. Necrosis has been rarely evaluated and discussed in the literature. Intraperitoneal injection of 30 mg/kg of hydrochloride cocaine is reported to cause necrosis and decrease the number of testis interstitial cells (
54). In a study carried out by Cansu et al., necrosis was not detected (
11). The responsible mechanism may be similar to the one explained for apoptosis. This finding also highlights the importance of investigating the cytotoxic effects of MPH. Congestion is also a matter of controversy that was considered in the present study. While congestion was higher in the MPH group, some studies did not detect significant congestion (
11) or any associated degrees (
7). To indicate limitations and strengths, we investigated a wide range of variables, including hormonal, spermatographic, and histopathologic characteristics, as well as weight. Furthermore, the two LD and HD groups were examined to illustrate dose-dependent changes. Chronic exposure could be another positive point in this regard. Some delayed or rebound effects were not presented at the termination point of medication in the study. Therefore, it is necessary to evaluate rats after medication termination. Additionally, given the probable role of weight loss in sexual dysfunction, this variable should be further investigated. In this respect, changes in weight, not the final weight, may be more accurate to assess the consequences of MPH therapy.